1 / 55

Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease:

Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease:. Assoc . Prof. Dr. Nurver Turfaner Department of Family Medicine. Key Points.

lloyd
Download Presentation

Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epidemiology of Lipids, LipidManagement and Risk forCoronary Heart Disease:

  2. Assoc. Prof. Dr. NurverTurfaner • Department of FamilyMedicine

  3. Key Points • Epidemiological studies have shown that a large percentage of the variation within and between countries in coronary heart disease (CHD) incidence can be accounted for by lipid-associated risk factors. • More than 90% of the population-attributable risk for CHD can be explained by potentially modifiable risk factors (lipids, blood pressure, body weight, diabetes, psychosocial factors, diet, and physical activity).

  4. Key Points Clinical trials have shown that each 1% reduction in low-density lipoprotein cholesterol (LDL-C) is associated with a reduction of approximately 1% in CHD risk. However, observational data suggest that the benefit may be as much as 3% CHD risk reduction per 1% decrement in LDL-C if maintained for many years.

  5. Key Points • The non-high-density lipoprotein cholesterol (non-HDL-C) level is highly correlated with the level of apolipoprotein B and is a better predictor of CHD risk than LDL-C in patients with elevated triglycerides (≥200 mg dl/1); therefore non-HDL-C goals have been established as secondary targets for patients with elevated triglycerides.

  6. Vascular Biology andAtherogenesis • Key Points • Arteries are highly evolved conduits comprised of multiple cellular and connective tissue layers. Atherogenesis is a diffuse, biochemically and histologically complex disease. • Endothelial dysfunction initiates a series of changes along the vessel wall predisposing to inflammatory cell infiltration, increased thrombotic tendency, and heightened inflammatory tone.

  7. Vascular Biology andAtherogenesis • Atherogenesis is driven by a highly orchestrated set of cell types, interleukins, cytokines, reactive oxygen species (ROS), and pro-oxidative enzymes. There is a continuum of disease beginning with the foam cell and progressing to fatty streaks and ultimately to raised atheromatous plaques.

  8. Vascular Biology andAtherogenesis • Sudden plaque rupture with overlying thrombus formation is the accepted etiology for acute coronary syndromes (ACS), including unstable angina and acute myocardial infarction (MI). Atheromatous plaque can undergo sudden transitions and rapidly progress from a stable to an unstable condition.

  9. Vascular Biology andAtherogenesis • Because the atherothrombotic process involves lipid deposition,endothelial dysfunction, inflammation and hemostasis, numerous targets exist through which lifestyle and pharmacologic interventions may be able to prevent or retard the process and improve clinical outcomes.

  10. Endothelial Cell Function and Dysfunction • Lipoproteins • Smoking • Cytokines • Turbulent flow • ROS • Glucose (AGE) • Hypertension • Vasoconstriction • Platelet aggregation

  11. Endothelial Cell Function and Dysfunction • SMC proliferation • Leukocyte adhesion • LDL oxidation • Activation of MMPs • Endothelial Dysfunction • ↓Nitric Oxide Activity • Endothelial Activation • ↑Adhesion Molecules

  12. Endothelial Cell Function and Dysfunction • Risk factors for cardiovascular disease are injurious to endothelial cells. Endothelial cells exposed to oxidized lipoproteins, increased blood pressure, hyperglycemia, or turbulent blood flow become dysfunctional.

  13. Endothelial Cell Function and Dysfunction • Dysfunctional endothelial cells upregulate the expression of adhesion molecules, reactive oxygen species, and PAI-1, and decrease the production of nitric oxide and tPA. This can lead to such proatherogenic changes as increased platelet and white cell adhesion, vasoconstriction, and smooth muscle cell proliferation, among other effects.

  14. Atherosclerosis and vascular remodeling. The traditional depiction of the progression of atherosclerosis entails increasing obstruction of a vessel’s lumen.

  15. Detection, Evaluation, andTreatment Goals for LipidDisorders in Adults • (NCEP ATP) III has established three major coronary heart disease (CHD) risk categories with corresponding low-density lipoprotein cholesterol (LDL-C) treatment goals: • – lower risk (0–1 risk factor, LDL-C goal <160 mg dl/1); • – moderate risk (2+ risk factors, LDL-C goal <130 mg dl/1); and • – higher risk (CHD or risk equivalent, LDL-C goal <100 mg dl/1).

  16. Detection, Evaluation, andTreatment Goals for LipidDisorders in Adults • A three-step process may be used to quickly identify the major CHD risk category: • Identify CHD or a risk equivalent (diabetes or clinical atherosclerosis), if present, this establishes an LDL-C goal <100 mg/ dl • For the remaining patients, major CHD risk factors are counted, if 0–1 major risk factors is present the LDL-C goal is <160 mg /dl

  17. Detection, Evaluation, andTreatment Goals for LipidDisorders in Adults • For those not yet classified, the Framingham risk score is calculated in order to determine whether the patient has a 10-year risk >20% (considered a CHD risk equivalent with an LDL-C goal <100 mg /dl) or a 10-year CHD risk ≤20% (LDL-C goal <130 mg/ dl).

  18. Treatment Goals • For patients with high or very high triglycerides (≥200 mg dl/1), non-high-density lipoprotein cholesterol (non-HDL-C) has been established as a secondary target of therapy (after the LDL-C goal has been achieved), with treatment goals that are 30 mg dl/1 above the corresponding LDL-C goals

  19. Treatment Goals • No specific treatment goals have been established by the NCEP for triglycerides or HDL-C per se, but therapeutic efforts to improve these lipids through lifestyle and drug therapy are encouraged and improvements in these lipids will normally occur as a byproduct of efforts to achieve LDL-C and non-HDL-C treatment goals.

  20. Evaluation NCEP AdultTreatment Panel III classification of lipoprotein and total cholesterol and triglyceride levels in adults. • LDL cholesterol (mg /dl) • <100 Optimal • 100–129 Near or above optimal • 130–159 Borderline high • 160–189 High • ≥190 Very high

  21. Evaluation • Total cholesterol (mg /dl) • <200 Desirable • 200–239 Borderline high • ≥240 High • HDL cholesterol (mg/ dl) • <40 Low • ≥60 High

  22. Triglycerides (mg /dl) • <150 Normal • 150–199 Borderline high • 200–499 High • ≥500 Very high

  23. Detection of Hyperlipidemia • A screening fasting lipid profile is recommended at least once every five years for all adults ≥20 years of age. A fasting lipid profile allows evaluation of total cholesterol, LDL-C (calculated), HDL-C, non-HDL-C, and triglyceride concentrations. If the screening lipid profile is nonfasting, it should be followed up with a fasting lipid profile if total cholesterol is ≥200 mg dl/1 or the HDL-C level is <40 mg dl/1.

  24. Detection of Hyperlipidemia • LDL-C = Total-C – HDL-C – VLDL-C • This equation can also be stated as follows using the Friedewaldformula • to estimate the VLDL-C concentration: • LDL-C = Total-C – HDL-C – Triglycerides • The Friedewald equation works well as long as the triglyceride concentration is not >400 mg /dl. When this is the case, the LDL-C level should be measured directly using either ultracentrifugation or one of several commercially available enzymatic methods. Alternatively, the non-HDL-C level (Total-C minus HDL-C) can be used to guide treatment.

  25. RISK STRATIFICATION • Major coronary heart disease risk factors (excluding LDL cholesterol)a . • Cigarette smoking • Hypertension • SBP ≥140 mmHg or DBP ≥90 mmHg • or use of antihypertensive medication • Family history of premature CHD • CHD in a male first degree relativeb <55 yr of age • CHD in a female first degree relativeb <65 yr of age

  26. Risk Stratification • Age • ≥45 yr of age for men • ≥55 yr of age for women • HDL cholesterol <40 mg/ dl • if ≥60 mg /dl, this counts as a “negative risk factor,” subtracting 1 from the total

  27. a LDL cholesterol is not included among the risk factors because the purpose of counting risk factors is to modify treatment of LDL. Diabetes is a coronary heart disease risk equivalent, so is not counted as a major risk factor in the ATP III classification system. • b First degree relatives include parents, siblings, and children.

  28. STEPS IN THE RISK STRATIFICATION PROCESS Adult Treatment Panel III risk categories and subcategories with corresponding LDL cholesterol treatment goals. Risk category LDL-C goal (mg dl/1) Lower risk: 0–1 risk factor <160 Moderate risk: ≥2 risk factorsa • 10-yr risk <10% <130 • 10-yr risk 10–20% <130, <100 (optional) High risk: CHD or risk equivalentb • Other than very high risk <100 • Very high risk <100, <70 (optional)

  29. Risk Stratification • a In the absence of CHD or a risk equivalent, 10-yr CHD risk estimates are based on the Framingham risk score. • b CHD includes history of myocardial infarction, any evidence of myocardial ischemia, or coronary artery disease. CHD risk equivalents include any form of non-CHD clinical atherosclerosis, multiple risk factors conferring 10-yr CHD risk >20%, or diabetes.

  30. VERY HIGH RISK PATIENTS, OPTIONALLDL-C GOAL <70 mg/dl • The ATP III recommends consideration of an optional LDL-C goal of <70 mg /dl for patients in the high risk group who have established cardiovascular disease plus any of the following: • 1. multiple major risk factors, especially diabetes; • 2. severe and/or poorly controlled risk factors, especially smoking; • 3. multiple risk factors of the metabolic syndrome, especially triglycerides ≥200 mg /dl non-HDL-C ≥130 mg /dl, HDL-C <40 mg/ dl • 4. acute coronary syndromes.

  31. MODERATELY HIGH RISK PATIENTS,OPTIONAL LDL-C GOAL <100 mg /dl • The NCEP ATP III recommends consideration of an optional LDL-C goal of <100 mg/ dl for patients whose FRS indicates an estimated 10-year event risk is in the range of 10–20% (moderately high risk).

  32. TREATMENT GOALS FOR PATIENTSWITH ELEVATED TRIGLYCERIDES • For patients with very high triglycerides (≥500 mg/ dl), the initial goal of therapy is to lower the triglyceride level to reduce the risk of acute pancreatitis. • Regarding CHD risk reduction, achievement of the LDL-C treatment goal is the target for lipid management.

  33. Treatment forHigh Triglycerides • For those with triglycerides ≥200 mg /dl, non-HDL-C goals have also been established as secondary treatment targets. • This is based on the premises that a normal VLDL-C level is ≤30 mg/ dl and that the VLDL-C concentration is highly correlated with the concentrations of atherogenic remnant lipoproteins

  34. Diseases and physiological or pharmacological perturbations associated with hyperlipidemia • Endocrine: Diabetes mellitus, Thyroid disease, Pituitary disease, Pregnancy • Hepatic disease: Cholestasis, Hepatocellular disease, Cholelithiasis • Renal disease: Nephrotic syndrome, Chronic renal failure • Immunoglobulin excess: Myeloma, Macroglobulinemia, Systemic Lupus erythematosus • Hyperuricemia

  35. Drugs: β-blockers, Thiazide diuretics, Steroid hormones, Microsomal enzyme-inducing agents (e.g:phenytoin, phenobarbitone, griseofulvin), Retinoic acid derivatives (e.g:isotretinoin), HIV antiretroviral therapy • Miscellaneous: Glycogen storage disease, Lipodystrophies • Nutritional: Obesity, Alcohol, Anorexia nervosa

  36. METABOLIC SYNDROME • The metabolic syndrome (MetS) is a cluster of risk factors for CHD and type 2 diabetes that includes: central obesity, elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-C), elevated blood pressure, and elevated glucose.

  37. Criteria for clinical diagnosis of metabolic syndrome • Measure (any 3 of 5 constitute Categorical cutpoints diagnosis of metabolic syndrome) • Elevated waist circumferencea,b • ≥102 cm in men • ≥88 cm in women • Elevated triglycerides ≥150 mg /dl • Or • On drug treatment for elevated triglycerides c

  38. Criteria for clinical diagnosis of metabolic syndrome • Reduced HDL-C • <40 mg /dl in men • <50 mg /dl in women • Or • On drug treatment for reduced HDL-C c • Elevated blood pressure ≥130 mmHg systolic blood pressure • Or • ≥85 mmHg diastolic blood pressure

  39. Criteria for clinical diagnosis of metabolic syndrome • Or • On antihypertensive drug treatment in a patient with a history of hypertension • Elevated fasting glucose ≥100 mg /dl • Or • On drug treatment for elevated glucose

  40. WAIST CIRCUMFERENCE • a To measure waist circumference, locate top of right iliac crest. Place a measuring tape in a horizontal plane around abdomen at level of iliac crest. Before reading the tape measure, ensure that tape is snug but does not compress the skin and is parallel to floor. Measurement is made at the end of a normal expiration.

  41. Therapeutic Lifestyle Changesin the Management of LipidDisorders • A western lifestyle characterized by low physical activity, a diet high in saturated fats and cholesterol, excess energy consumption and a substantial prevalence of cigarette smoking is associated with the development of numerous coronary heart disease (CHD) risk factors, including dyslipidemias, hypertension, obesity, diabetes, and inflammatory and hypercoagulable states

  42. Therapeutic Lifestyle Changes • The primary target of TLC is to reduce low-density lipoprotein cholesterol (LDL-C) to the target level. Secondary targets include achieving non-HDL-C goals and improvements in the components of the MetS. The main features of the TLC recommendations include

  43. Therapeutic Lifestyle Changes • The main features of the TLC recommendations include: • reduced intakes of saturated fats (<7% of energy) and cholesterol (<200 mg /day); • dietary adjuncts for lowering LDL-C, including plant sterols/stanols (2 g /day) and increased intake of viscous fibers (10–25 g/day); • weight reduction if overweight or obese; • increased physical activity.

  44. Nutrient composition of the therapeutic lifestyle NutrientRecommended intake • Saturated fat a <7% of total calories • Polyunsaturated fat Up to 10% of total calories • Monounsaturated fat Up to 20% of total calories • Total fat 25–35% of total calories • Carbohydrate b 50–60% of total calories • Fiber 20–30 g/ day • Protein Approximately 15% of total calories • Cholesterol <200 mg/ day

  45. Therapeutic Lifestyle Changes • a Trans fatty acids are another LDL-raising fat that should be kept at a low intake. • b Carbohydrate should be derived predominantly from foods rich in complex carbohydrates including grains, especially whole grains, fruits, and vegetables. • c Daily energy expenditure should include at least moderate physical activity (contributing approximately 200 kcal/ day).

  46. Characteristics of a low-risk dietary pattern consistentwith the National Cholesterol Education Program therapeutic life-style changes diet. Foods to be emphasized Foods to be eatensparingly • Whole grains Refined grains • Legumes White rice and potatoes • Nuts and oils Stick margarines and shortenings • Fruits and vegetables Sodas, sweets, and desserts • Fish and lean meats High-fat meats • Low-fat dairy products High-fat dairy products

  47. DIETARY ADJUNCTS: VISCOUS FIBERS AND PLANT STEROL/STANOL PRODUCTS • whole oats and barley, certain fruits such as prunes and pears, and some bulk fiber • laxatives including Metamucil and Citrucel • Several plant sterol and/or stanol-containing products are available in grocery stores including margarine-like spreads, yogurts, snack bars, and dietary supplements

  48. PHYSICAL ACTIVITY AND WEIGHTREDUCTION • The current recommendations regarding physical activity are for all Americans to engage in 30–60 min of activity on most days or ∼1000 kcal per week . Walking is the most practical form of exercise for most people and the average middle-aged man or woman can walk approximately 2 miles in 30 min. A useful rule of thumb is that the number of kcal required to walk a mile is approximately equal to 0.67 times body weight in pounds. • Thus, a 150-pound woman will burn about 100 kcal for each mile walked. • The corresponding number for a 200-pound man would be 134 kcal.

  49. PHYSICAL ACTIVITY • In addition, regular physical activity is extremely important for weight management. It is not necessary to achieve ideal body weight in order for weight loss to have an important impact on the CHD risk factor profile. • Additional LDL-C lowering might be achieved by loss of 5–10% of body weight if the patient is overweight or obese. Thus, it is possible to obtain reductions of up to 30% in LDL-C with aggressive dietary and lifestyle management.

  50. SMOKING CESSATION • In addition to being a major CHD risk factor itself, cigarette smoking is associated with adverse changes in numerous CHD risk markers, including levels of triglycerides, HDL-C, insulin resistance, fibrinogen, and other hemostatic and inflammatory markers. For patients who smoke, clinicians should strongly encourage them to quit. For patients who are unwilling or unable to do so, efforts to limit smoking should be encouraged and the significance of managing lipids and other CHD risk factors is heightened.

More Related